114 The Impact Of Intralesional Xiaflex On Psychosocial Outcomes in Men with Peyronie’s Disease (PD)

Abstract

Peyronie’s disease (PD) is associated with significant bother and even depression in some men. To evaluate bother and depression in men with PD patients undergoing treatment with ILX. Men meeting the criteria for ILX underwent up to 8 injections divided into 4 cycles. At-home modeling was conducted by the patients. Curvature assessment was done prior to treatment, mid-treatment (after ILX #4) and after completion (ILX #8). All ILX patients completed validated questionnaires including the Peyronie’s Disease Questionnaire bother domain (PDQB, max score 16) and the Center for Epidemiologic Studies Depression Scale (CES-D, max score 60). Greater than 10° change was considered significant. Comparison between patients who improved, remained unchanged or worsened was performed. Overall and subgroup analyzes were done including Wilcoxon-Mann-Whitney, Friedman and Kruskal Wallis test. 48 patients are currently evaluable. Mean age was 57±9.6 years. Mean PD duration was 17±28.4 months. Mean curvature, CESD score and PDQB score for each time point are reported in Table 1. Only curvature significantly improved. On sub-group analyzes of patients who improved vs. those who worsened, after ILX#4, there was a mean change on CESD of -1.06 vs -4.3 and PDQB of -1.2 vs +1.5, respectively. After ILX #8, those changes were: CESD +3.5 vs. +3.6 and PDQ of -3 vs -1 respectively. None of them were significantly different across groups at any treatment point. Finally, to evaluate clinically significant PD related bother and depressive symptoms during treatment, percentage of patients with PDQB>9 and CESD>16 was calculated. The percentage of patients with PDQ>9 and CESD>16 were 60% and 27% at baseline, 59% and 27% after ILX#4, and 50% and 39% after ILX#8, respectively. Despite this trend towards decreased bother, differences did not reach statistical significance.